Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …

Studies of neurocognitive function in patients with schizophrenia use widely variable
assessment techniques. Clinical trials assessing the cognitive enhancing effect of new …

Cognitive dysfunction is a core feature of schizophrenia. Deficits are moderate to severe
across several domains, including attention, working memory, verbal learning and memory …

BACKGROUND: Although cognitive impairment is described as a core component of the
characterization of schizophrenia, a sizable percentage of patients are classified as …

Despite the widespread acceptance of the neurodevelopmental model of schizophrenia, its
application to research concerned with the prodromal phase of illness is limited. Little …

Cognition denotes a relatively high level of processing of specific information including
thinking, memory, perception, motivation, skilled movements and language. Cognitive …

These guidelines for the biological treatment of schizophrenia were developed by an
international Task Force of the World Federation of Societies of Biological Psychiatry …

Although the neurotransmitter dopamine plays a prominent role in the pathogenesis and
treatment of schizophrenia, the dopamine hypothesis of schizophrenia fails to explain all …

Background: Truly effective treatments for schizophrenia require much more than clinical
efficacy. Symptom improvement is all that is required to demonstrate clinical efficacy …